ERBB2 and breast carcinoma: Unlike hormone receptor-positive type or HER2-type breast cancer, there is currently limited therapeutic targets for TNBC, Although immune checkpoint inhibitors are now applied in TNBC in combination with chemotherapy (43, 44), demanding on targeted therapy is still existed, and YAP1 could be the one of candidate of potential therapeutic target.